1Huang YS,Chern HD,Su WJ,et al.Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.Hepatology,2002,35(4):883-839
2Huang YS,Chern HD,Su WJ,et al.Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.Hepatology,2003,37(4):924-930
3Sharma SK,Balamurugan A,Saha PK,et al.Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.Am J Respir Crit Care Med,2002,166(7):916-919
4Yee D,Valiquette C,Pelletier M,et al.Incidence of serious side from first-line antituberculosis drugs among patients treated for active tuberculosis.Am J Respir Crit Care Med,2003,167(11):1472-1477
5Tiwari VK.Alcoholic hepatic impairment complicating treatment with hepatotoxic antituberculosis drugs.J Indian Med Assoc,1996,94(9):347-348
6Ungo JR,Jones D,Ashkin D,et al.Antituberculosis drug-induced hepatotoxicity:the role of hepatitis C virus and the human immunodeficiency virus.Am J Respir Crit Care Med,1998,157(6 pt 1):1871-1876
7Ohkawa K,Hashiguchi M,Ohno K,et al.Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.Clin Pharmacol Ther,2002,72(2):220-226
8Roy B,Chowdhury A,Kundu S,et al.Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ''null'' mutation.J Gastroenterol Hepatol,2002,16(90):1033-1037
